Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Toward Pd-Free Pharma: Iron Catalysis in Cross-Coupling Reactions for Medicinal Chemistry

Objective

IRONMED aims to unlock a new, iron-based cross-coupling platform for the synthesis of complex small-molecule pharmaceuticals and to demonstrate its commercial potential. Modern drug manufacture relies almost exclusively on palladium-catalysed cross-couplings to construct biaryl and alkyl–aryl motifs that pervade antivirals, oncology drugs and CNS agents. This creates structural dependence on a scarce, expensive and geopolitically sensitive metal, and drives significant costs for catalyst, purification and compliance with strict metal-residue limits, with negative implications for affordability and supply resilience. Building on the PI’s recent advances, IRONMED will exploit a family of well-defined, ligand-controlled iron complexes that have already been shown to perform demanding transformations under mild conditions and to construct representative biaryl and alkyl–aryl bonds with high yields and a well-understood mechanism. The project will translate this chemistry from advanced academic results (TRL 2–3) to a pharma-relevant technology (TRL 4) by (i) adapting and validating iron-catalysed cross-couplings on selected drug-like building blocks and fragments of real or representative active ingredients, (ii) benchmarking them directly against state-of-the-art palladium processes in terms of yield, robustness, metal residues, purification needs and indicative cost of goods, and (iii) co-developing with industrial stakeholders a small set of standardised protocols, decision guidelines and business models (reagent, process/IP or service-based). By integrating technical data with techno-economic and market analyses, IRONMED will identify the most promising application niches and define clear go/no-go paths towards scale-up and follow-on funding. IRONMED will deliver a credible alternative catalytic platform that reduces dependence on palladium, improves process sustainability and opens new options for cost-effective access to advanced medicines.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2026-POC

See all projects funded under this call

Host institution

TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Net EU contribution
€ 150 000,00
Address
SENATE BUILDING TECHNION CITY
32000 Haifa
Israel
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)